Docket No. 434-226

Patent

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

THOMAS TOBIN

Serial No.: (

09/865,175

Filed:

May 24, 2001

For:

NOVEL LONG ACTING,

REVERSIBLE VETERINARY SEDATIVE AND ANALGESIC

AND METHOD OF USE

COPY OF PAPERS ORIGINALLY FILED WAR 0 7 20 PAPERS ORIGINAL WAR 0 PAPERS ORIGINA

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicant discloses to the Examiner under 37 CFR 1.56, and 37 CFR 1.97-1.98, as revised (1135 OG 13) and effective March 16, 1992, the information listed on the attached form PTO - 1449. This information may be found to be material to this invention under the current applicable patent law and as interpreted by the US PTO Rules, as cited above. Review and consideration of the listed references/information during substantive examination of this application is respectfully requested.

Applicant specifically emphasizes that this statement, and/or the act of providing copies of these references, is not to be construed as an admission that all or any of the references are prior art to the specific invention disclosed and claimed.

1 ( 1 (b)

JAN 3 0 2002 B

Also, nothing in this statement is to be construed as a representation that the

is the only material information to be found, or the best. It, however, is the only information to the applicant at this time that is believed to meet the "materiality standard" of the law. If any additional qualifying reference or other information is discovered in the future it will be submitted promptly to fulfill applicant's continuing duty of disclosure under CFR 1.99.

Respectfully submitted,

KING AND SCHICKLI PLLC

S.N. 09/86

JW. Seanor, DVM Registration No. 40,804

247 North Broadway Lexington, KY 40507 (859) 252-0889

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Weshington D.C. 20031 on 12/17/0/

Washington, D.C. 20231, on 12/17/0